Mitoxantrona en altas dosis asociada al uso de factores estimulantes de colonias de tejido hematopoyético (FECs) en reinducción de leucemias agudas

Santillana, Sergio; Medina, R; Kahatt, C; Gomez, H; Carracedo, C; Casanova, L; Valdivia, S; Otero, J; Rodríguez, W; Vallejos, C.
Arch. med. interna (Montevideo) ; (suppl.1997): 46, 1997.
Artículo en Español | URUCAN | ID: bcc-1845

Documentos relacionados

  1. Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.
  2. T/myeloid MPAL: origin and pathogenesis.
  3. Diagnostic workup of acute leukemias of ambiguous lineage.
  4. Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia.
  5. Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.
  6. Deubiquitinating enzyme inhibitor alleviates cyclin A1-mediated proteasome inhibitor tolerance in mixed-lineage leukemia.
  7. Clinical characteristics, biological profile, and outcome of biphenotypic acute leukemia: a case series.
  8. Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study.
  9. Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series.
  10. Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia.